Compare Hims and Hers Health Inc (HIMS) vs Sunrun Inc (RUN) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

Sunrun (RUN) trades at $7.58, down 0.39% on the day, reflecting a bearish technical trend. The stock shows attractive valuation ratios with a P/E of 5.16 and P/S of 0.59, while recent quarterly earnings have consistently beaten expectations. However, cash flow from operations remains negative, and the company faces headwinds from high borrowing costs impacting the solar sector. Positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing.

The outlook is mixed: strong analyst support with a $16.33 price target suggests significant upside, but operational cash burn and sector volatility pose risks. Investors should weigh low valuations against execution challenges and macroeconomic pressures affecting solar financing.